QLM-1016

N/A

Report date: 2026/05/11 20:01:57

Base Information

Drug NameQLM-1016
Drug Alias NameQLM1016QLM-1016
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor partial agonistsDopamine D3 receptor partial agonists +[6] 
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptorDopamine D3 receptor +[6] 
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSchizophrenia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A